Ozempic (semaglutide) and Saxenda (liraglutide): vigilance required due to potentially harmful falsified products

Article warns of falsified Ozempic and Saxenda products, including falsified pens containing insulin, and asks healthcare professionals to remain vigilant for symptoms linked to hypoglycaemia in patients who may have obtained and administered such a product.

SPS commentary:

If a suspected falsified product is encountered, it should be quarantined and reported to the Yellow Card Scheme. Patients and the public should be reminded to only obtain prescription-only medicines from legal pharmacies and with a prescription from a qualified healthcare professional.

Medicines and Healthcare products Regulatory Agency